Epitranscriptomic Therapies Market Report 2026

Epitranscriptomic Therapies Market Overview

• Epitranscriptomic Therapies market size has reached to $1.56 billion in 2025 • Expected to grow to $4.2 billion in 2030 at a compound annual growth rate (CAGR) of 21.9% • Growth Driver: The Rise In Demand For Personalized Medicine Driving The Growth Of The Market Due To Tailored Patient-Specific Treatments Improving Efficacy And Outcomes • Market Trend: Collaborative Approaches Accelerate Development Of Ribonucleic Acid -Focused Cancer Therapies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Epitranscriptomic Therapies Market?

Epitranscriptomic therapies refer to medical treatments that target chemical modifications on ribonucleic acid molecules, such as messenger ribonucleic acid and non-coding ribonucleic acids, to regulate gene expression without altering the underlying deoxyribonucleic acid sequence. These therapies are designed to modulate cellular functions and biological processes, offering potential applications in treating cancer, genetic disorders, and other complex diseases. The main types of epitranscriptomic therapies include small molecule inhibitors, ribonucleic acid modifying enzymes, antisense oligonucleotides, and other therapy types. Small molecule inhibitors refer to chemical compounds designed to target specific RNA-modifying enzymes for therapeutic purposes. These therapies are administered via injectable, oral, and other routes of administration. The applications include cancer, neurological disorders, metabolic diseases, infectious diseases, and other applications, and the end users are hospitals, research institutes, pharmaceutical and biotechnology companies, and other end users.

What Is The Epitranscriptomic Therapies Market Growth Forecast?

The epitranscriptomic therapies market size is expected to see exponential growth in the next few years. It will grow to $4.2 billion in 2030 at a compound annual growth rate (CAGR) of 21.9%. The growth in the forecast period can be attributed to increasing investments in rna-based therapeutics, rising demand for targeted cancer treatments, expansion of personalized medicine approaches, growing clinical trial activity in epitranscriptomics, increasing regulatory engagement for novel rna therapies. Major trends in the forecast period include increasing development of epitranscriptomic drug pipelines, growing use of rna modification profiling tools, expansion of combination epitranscriptomic therapies, rising integration of bioinformatics in therapy design, enhanced focus on precision medicine applications.

Global Epitranscriptomic Therapies Market Segmentation

1) By Therapy Type: Small Molecule Inhibitors; Ribonucleic Acid Modifying Enzymes; Antisense Oligonucleotides; Other Therapy Types 2) By Route of Administration: Injectable; Oral; Other Routes Of Administration 3) By Application: Cancer; Neurological Disorders; Metabolic Diseases; Infectious Diseases; Other Applications 4) By End-User: Hospitals; Research Institutes; Pharmaceutical And Biotechnology Companies; Other End-Users Subsegments: 1) By Small Molecule Inhibitors: Methyltransferase Inhibitors; Demethylase Inhibitors; Reader Protein Inhibitors; Writer Enzyme Inhibitors; Eraser Enzyme Inhibitors 2) By Ribonucleic Acid Modifying Enzymes: Methyltransferase Enzymes; Demethylase Enzymes; Pseudouridine Synthase Enzymes; Adenosine Deaminase Enzymes; Cytidine Deaminase Enzymes 3) By Antisense Oligonucleotides: Gapmer Oligonucleotides; Splice Modulating Oligonucleotides; Translation Blocking Oligonucleotides; Exon Skipping Oligonucleotides; Gene Expression Silencing Oligonucleotides 4) By Other Therapy Types: Ribonucleic Acid Interference Based Therapies; Messenger Ribonucleic Acid Editing Therapies; Epitranscriptomic Vaccine Platforms; Gene Regulation Modulation Therapies; Combination Epitranscriptomic Therapies

What Is The Driver Of The Epitranscriptomic Therapies Market?

The increasing demand for personalized medicine is expected to propel the growth of the epitranscriptomic therapies market going forward. Personalized medicine refers to a medical approach that tailors healthcare decisions, treatments, and interventions to the individual characteristics of each patient, such as their genetic profile, lifestyle, and environment. The increasing demand for personalized medicine is primarily driven by the rising prevalence of chronic and complex diseases, as tailored treatments can more effectively target individual patient needs and improve outcomes. Personalized medicine supports epitranscriptomic therapies by customizing treatments to an individual’s specific RNA modification patterns, enhancing therapeutic effectiveness while reducing the risk of adverse effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the increasing demand for personalized medicine is driving the growth of the epitranscriptomic therapies industry.

Key Players In The Global Epitranscriptomic Therapies Market

Major companies operating in the epitranscriptomic therapies market are AstraZeneca PLC, GSK plc, Moderna Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Arrakis Therapeutics Inc., AIRNA Corporation, CD Genomics, ProQR Therapeutics N.V., Nimbus Therapeutics LLC, Envisagenics Inc., Skyhawk Therapeutics Inc., Avidity Biosciences Inc., STORM Therapeutics Ltd., Omega Therapeutics Inc., Korro Bio Inc., Accent Therapeutics Inc., Alida Biosciences Inc., and O2nix Bio.

Global Epitranscriptomic Therapies Market Trends and Insights

Major companies in the epitranscriptomic therapies market are focusing on adopting strategic partnerships to develop innovative RNA‑modifying cancer therapies. Strategic partnerships are cooperative arrangements where organizations combine resources, knowledge, or strengths to pursue shared objectives that drive faster growth, lower operational risks, and enhance market competitiveness. For instance, in January 2026, STORM Therapeutics Ltd., a UK-based biotechnology company, partnered with Alida Biosciences Inc., a US-based technology company, to advance cancer therapies targeting epitranscriptomic mechanisms. The collaboration focuses on integrating AlidaBio’s EpiPlex and EpiScout platforms with STORM’s clinical trials of STC‑15, a first-in-class METTL3 inhibitor. This partnership aims to identify and validate m6A RNA modification biomarkers that can predict patient responses and optimize therapeutic strategies. The collaboration combines drug development with advanced RNA profiling, marking a major step forward in epitranscriptomic cancer therapies.

What Are Latest Mergers And Acquisitions In The Epitranscriptomic Therapies Market?

In June 2025, Synfini Inc., a US-based biotechnology company, partnered with O2nix Bio Inc. to co-develop novel cancer therapeutics targeting FTSJ1, a tRNA-modifying enzyme involved in metastatic cancer cell survival. This partnership aims to advance the development of epitranscriptomic-based therapies by combining O2nix Bio’s expertise in RNA epitranscriptomics and cancer metastasis biology with Synfini’s AI-driven drug discovery platform that integrates computational design, automated synthesis, and testing. O2nix Bio Inc. is a US-based biotechnology company specializing in RNA biology and epitranscriptomic mechanisms driving cancer metastasis.

Regional Insights

North America was the largest region in the epitranscriptomic therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Epitranscriptomic Therapies Market?

The epitranscriptomic therapies market consists of revenues earned by entities by providing services such as research and development services, contract research organization services, clinical trial services, epitranscriptomic profiling services, bioinformatics and data analysis services, regulatory and consulting services and manufacturing, and process development services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Epitranscriptomic Therapies Market Report 2026?

The epitranscriptomic therapies market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the epitranscriptomic therapies industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.